Loading...
•
Apr 02, 2022
Haemonetics Q4 2022 Earnings Report
Haemonetics' Q4 2022 financial results were reported, showing revenue increase and strong performance in Hospital business unit.
Key Takeaways
Haemonetics reported a strong fourth quarter, with revenue up 17.8% to $265 million. The company saw growth across its business units, particularly in Hospital, and managed to mitigate inflationary pressures through its Operational Excellence Program. Adjusted earnings per diluted share increased by 41.3% to $0.65.
Revenue increased by 17.8% to $265 million.
Organic revenue increased by 18.9%.
Adjusted earnings per diluted share increased by 41.3% to $0.65.
Operating income was $19.2 million, compared to an operating loss of $21.2 million in the same period last year.
Revenue by Segment
Forward Guidance
The Company issued its fiscal 2023 GAAP total revenue growth guidance of 5 – 9% and organic revenue growth guidance as follows:Organic1Total revenue6 - 10%Plasma revenue7 - 12%Hospital Revenue16 - 19%Blood Center revenue(4 - 7%)
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...